Navigation Links
Ceremed's OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
Date:2/5/2008

LOS ANGELES, Feb. 5 /PRNewswire/ -- New polymer material designed to stop bone bleeding in surgery reduces the risk of surgical infection, according to a new animal study to be published in the February 2008 issue of Clinical Orthopaedics and Related Research (CORR). The study has implications for lowering the risk of hospital-acquired infections, including MRSA.

Researchers from the Medical University of South Carolina at Charleston and Keck School of Medicine at the University of Southern California in Los Angeles compared newly available polymer, Ostene(R), with bone wax, traditionally used to stop bone bleeding in surgically cut bone surfaces. The scientists looked at the two materials' effect on bone infection in the presence of Staphylococcus Aureus, similar to the organism that is responsible for MRSA. The results showed that, when exposed to bacteria, the bones treated with Ostene(R) were four times less likely to get infected than the bones treated with bone wax, 100% of which developed infection. The study also showed that the bones treated with Ostene(R) healed normally, while the presence of bone wax inhibited bone growth.

Bone wax, a beeswax-based product, is the least expensive and most commonly used bone hemostasis material despite its well-documented side effects: Numerous studies indicate that bone wax interferes with the body's ability to clear bacteria and increases the risk of hospital-acquired infections; it is also known to inhibit bone growth and bone healing after surgery.

Ostene(R) offers an alternative that does not increase the risk to patient. Its use in place of bone wax may help reduce serious post-operative complications, including sternal wound infection and the separation of the sternum. The material is used in cardiac, orthopedic, oral, and neurosurgery. Other applications under development include the use of Ostene(R) as a safe, soluble delivery vehicle for a variety of therapeutic agents, from antibiotics to bone growth factors. Ostene(R) is authorized for sale both in the U.S. and the European market.

Ostene(R) is a sterile mixture of water-soluble alkylene oxide copolymers developed as an affordable, easy-to-handle synthetic bone hemostasis material that reduces the overall risk of post surgical infections, sternal non-union, poor bone healing and chronic inflammation. Wax-like and malleable during application, the biomaterial dissolves rapidly and is eliminated from the body shortly after surgery. The material's main polymer component inherently reduces bacterial adhesion. Ostene(R) is the only available product designed to stop bone bleeding in surgery that does not interfere with bone healing or add the risk of surgical infections, including MRSA.

The results of the USC/MUSC study suggest that the use of Ostene(R) may have implications for reducing the risk of surgical site infection and for improving post-operative healing and recovery. The benefits of Ostene(R) may be particularly significant in lowering the rates of serious complications following cardiac surgery, especially among a growing high-risk group of diabetic and overweight patients, who currently represent at least 25% of the 640,000 open heart surgery procedures performed each year in the US.

"Ostene(R)'s unique properties are particularly significant now that we are battling the threat of hospital-acquired infections, especially MRSA," Ceremed's president and CEO Tadeusz Wellisz, M.D., commented on the study. "Ceremed is currently developing the next generation of Ostene(R) with antibiotics, specifically designed to prevent hospital-acquired surgical infection."

About The Company:

Ceremed, Inc. is a privately held medical device corporation formed in 2002 by a surgeon and a group of scientists from the University of Southern California. The company has unique expertise and a portfolio of innovative proprietary technology in the field of soluble alkylene oxide copolymers. These polymers have multiple medical applications, including bone hemostasis and a delivery system for a variety of therapeutic agents.

For additional information about the product or the Company, please contact Danielle Nolan at 310-815-2125 or info@ceremed.com.

For copies of the study please go to: http://www.springerlink.com/content/rk727126p2385460/fulltext.pdf Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Tadeusz Wellisz http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=72918


'/>"/>
SOURCE Ceremed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy
2. Study Finds Starion Instruments Tissue Welding Technology Reduces Pain and Bleeding in Tonsillectomy Patients
3. Surgeons Develop Innovative Life-Saving Treatments to Correct Massive Bleeding in Trauma Patients
4. Stem Cell Breakthrough Advances Science Without Ethical Landmines, Says Cardinal
5. Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo
6. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
7. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
8. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
9. Zetia Does Not Reduce Carotid Plaque Size When Added to Zocor
10. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
11. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... -- Global Paclitaxel Market 2016 Industry Research ... and the Paclitaxel analysis in this study is supported ... its players. This is the latest Paclitaxel ... current state of the industry while providing a basic ... industry chain structure. The Paclitaxel market analysis is provided ...
(Date:5/23/2016)... , May 23, 2016 The World Health ... PrePex device to include adolescents aged 13 years, and ... can be offered for adult and adolescent males in the ... . PrePex was the first male circumcision device to ... MedTech,s CEO, Eddy Horowitz said: " The ...
(Date:5/23/2016)... May 23, 2016   Purdue Pharma L.P. ... an agreement with Egalet Corporation and Acura Pharmaceuticals, ... part of the agreement the companies will exchange ... all three companies to develop and sell several ... "This agreement reflects the commitment of Purdue Pharma ...
Breaking Medicine Technology:
(Date:5/23/2016)... ... May 23, 2016 , ... On Sunday, May 15, Rockynol ... 64-room assisted living center. After 18 months of construction, the new state-of-the-art structure ... building provides the latest in assisted living amenities and services, offering six different ...
(Date:5/23/2016)... Los Angeles, CA (PRWEB) , ... May 23, 2016 , ... ... bariatric surgeons have noted that, less than 1% of United Kingdom residents who could ... the UK’s National Health Service (NHS) increases the number of bariatric procedures it offers ...
(Date:5/23/2016)... ... May 23, 2016 , ... African-American ... to Georgia State University researchers. , In a recent study published ... and seventh grades shared their experiences with strained relationships, recurring violence, internalized ...
(Date:5/23/2016)... ... May 23, 2016 , ... ComplianceOnline, the leading governance, risk ... medical device summit on September 15 and 16, 2016 in San Diego, CA. ... FDA office bearers will be one of the largest gatherings of medical device companies, ...
(Date:5/23/2016)... PALMYRA, Wis. (PRWEB) , ... May 23, 2016 ... ... held April 29 on its Chesterfield, Missouri, campus, Standard Process Inc. ... Kate Cline, Stephanie Siewert and Chloe Tillman. Each student is in her fifth ...
Breaking Medicine News(10 mins):